Concentrations of soluble tumor necrosis factor receptors, β2-microglobulin, IL-6 and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme-chemotherapy

International Journal of Immunotherapy

Volumn 13, Issue 3-4, 1997, Pages 121-130

  Desser, L ^a,c   Sakalova A ^b   Zavadova E ^a   Holomanova D ^b   Mohr, T ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Physics and Informatics   (Slovakia)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CHYMOTRYPSIN; ENZYME; INTERLEUKIN 6; PAPAIN; TRYPSIN; TUMOR MARKER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; WOBE MUGOS;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER REGRESSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

EID: 0031396359     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Niesvizky R , Siegel D., and Michaeli J Biology and treatment of Multiple Myeloma. Blood Reviews, 7, 24, 1993.
2. Mandelli F , Arcese W., Avisat G. The interferons in hematological malignancies. Balliere's Clin Hematol , 7, 91, 1994
3. Desser L , Rehberger A., and Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. Cancer Biother., 9, 253, 1994.
4. Zavadova E., Desser L., and Mohr T. Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biotherapy, 10, 147, 1995.
5. Wrba H. Krebstherapie mit proteolytischen Enzymen. In: Wrba, H. (ed.). "Kombinierte Tumortherapie" Hippokrates, Stuttgart, 1990.
6. Wolf M., Ransberger K "Enzymtherapie". Maudrich, Vienna, 1970.
7. Ambrus J L , Lassman H.B , Demarch J J Absorption of exogenous and endogenous proteolytic enzymes. Clin. Pharmacol. Therap., 8, 362, 1967.
8. 3H-markiertem Enzymgemisch (Wobenzym®). Acta Med. Austriaca, 6, 13, 1979.
9. Streichhan P., Pollinger W, Ransberger K Resorption partikulärer und makromolekularer Darminhaltsstoffe. Nat und Ganzheitsmed., 1, 90, 1988.
10. Dittmar FW, Luh W. Treatment of fibrocystic mastopathy with hydrolytic enzymes Int J Exp. Clin. Chemother , 6, 9, 1993
11. Cuzick J., Cooper E.H., MacLennan I C.M. The prognostic value of serum β2 microglobulin compared with other presentation features in myelomatosis Br J. Cancer, 52, 1, 1985.
12. Bataille R., Boccadoro M., Klein B , Durie B and Pileri A., C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system Blood, 80, 733, 1992
13. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med , 172, 599, 1990.
14. Ulich R T., Yin S , Remick D.G., Russel D , Eisenberg S P , Kohno T. Intratracheal administration of endotoxin and cytokines. Am. J Pathol., 142, 1335, 1993
15. Ythier A , Gascon M.P., Juillard P , Vesin C., Wallach D , and Grau G E Protective effect of natural TNF-binding protein on human TNF-induced toxicity in mice. Cytokine, 5, 459, 1993.
16. Aderka D , Engelmann H , Maor Y., Brakebusch C , Wallach, D Stabilization of the bioactivity of tumor necrosis factor by its soluble receptor J Exp Med., 175, 323, 1992.
17. De Groote D., Grau G E., Dehari I., Franchimont P Stabilization of functional tumor necrosis factor-a by its soluble NF-receptors Eur Cytokine New , 4, 359, 1993
18. Aderka D., Engelmann H., Shemer-Avni Y , et al. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res., 11, 157, 1992.
19. Schroder J., Stuber F., Gallati H., Schade F.U., Kremer B. Pattern of soluble TNF receptors I and II in sepsis. Infection, 23, 143, 1995.
20. Brockhaus M., Bar-Khayim Y., Gurwicz S., Frensdorff A., Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int., 42, 663, 1992.
21. Heilig B., Wermann M., Gailati H , et al. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin. Invest., 70, 22, 1992.
22. Aderka D., Wysenbeek A., Engelmann H., et al Correlation between serum level of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum., 36, 1111, 1993
23. Bilello J.A., Stellrecht K., Drusano G.L., Stein D.S Soluble tumor necrosis factor alpha receptor type II (sTNF alpha RII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients. J Infect. Dis , 173, 464, 1996
24. Langkopf F, Atzpodien J. Soluble tumor necrosis factor receptors as prognostic factors in cancer patients Lancet, 344, 57, 1994.
25. Gruss H J , Dolken G , Brach M. A., Mertelsmann R., Herrrnan F The significance of serum level of soluble 60 kDa receptors for tumor necrosis factor in patients with Hodgkin's disease Leukemia, 7, 1339, 1993
26. Reibnegger G , Diez-Ruiz A., Fuchs D., and Wachter H. Soluble tumor necrosis factor receptors as prognostic factors in cancer Lancet, 344, 8923, 1994.
27. Diez-Ruiz A., Tilz G P, Zangerle R , Baierbitterlich G., Wachter H., Fuchs, D. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. Eur J Hematol., 4, 1, 1995.
28. Denz H , Orth B , Weiss G , et al. Serum soluble tumor necrosis factor receptor 55 is increased in patients with hematologrcal neoplasia and is associated with immune activation and weight loss Eur J Cancer, 29A, 2232, 1993
29. Salles G., Bienvenu J., Bastion Y., et al Elevated circulating levels, of TNF-alpha and p55 soluble receptor are associated with a adverse prognosis in lymphoma patients. Br. J. Hematol., 93, 352, 1996
30. Lantz M., Malik S., Slevin M , Olsson I. Infusion of Tumor necrosis factor (TNF) causes an increase in circulating TNF-binding proteins in humans Cytokine, 2, 404, 1990
31. Bargetzi M.J , Lantz M., Smith C.G , et al. Interleukin 7-β induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in numaris Cancer Res , 53, 4010, 1993.
32. Bemelmans M A H., Gouma D J , Buurman W.A. LPS-induced sTNF-receptor release in vivo in a murine model J of Immunol , 151 5554, 1993
33. Godfried M.H., van der Poll T., Jansen J., et al Soluble receptors for tumor necrosis factor: a putative marker of disease progression in HIV infection. AIDS, 7, 33, 1993.
34. Onsrud M., Shabana A , Austgulen R., Nustad K Comparison between soluble tumor necrosis factor receptors and CAT25 in peritoneal fluids as a marker for epithelial ovarian cancer. Gynecol. Oncol , 57, 183, 1995.
35. Andus T., Gross V., Holstege A., et al. High Concentration of soluble tumor necrosis factor receptors in Ascites. Hepatology, 16, 749, 1992
36. Digel W., Porzsolt F , Schmid F., Herrmann F., Lesslauer W., Brockhaus M. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocyte leukemia. J. Clin. Invest , 89, 1690, 1992.
37. Billard C., Sigaux F., Wietzerbin J IFN-α in vivo enhances tumor necrosis factor receptor levels on hairy cells J. Immunol , 145, 1713, 1990
38. Klein B., Lu Z.Y., Gaillard J.P., Harousseau J L., Bataille, R. Inhibiting IL-6 in human multiple myeloma. Curr. Top. Microbiol. and Immunol., 182, 237, 1992
39. Bataille R., Jourdan M , Zhang X-G., Klein B. Serum level of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias J Clin. Invest, 84, 2008, 1989.
40. Pelliniemi TT., Irjala K., Mattila K., et al, for the Finnish Leukemia Group Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 85, 765, 1995
41. Dune B.G.M., Salmon S.E. A clinical staging system for multiple myeloma. Cancer, 36, 842, 1975.
42. Sakalová A., Holomanová D., Mikulecky M., Mistrik M., Lipsic T., Steruska M. Prognostic value of plasma-cell immunophenotype in patients with multiple Myeloma. Neoplasma, 40, 351, 1993.
43. Sakatová A., Vanasek J., Blaha M., Tichy M., Zadak Z. "Multiple myeloma and paraproteinemias". Slovak Academic Press, Bratislava, 1995.
44. Neuner P , Klosner G., Pourmojib M , Trautinger F., Knobler R. Selective release of tumor necrosis factor binding protein II by malignant human epidermal cells reveals protection from tumor necrosis factor-a mediated cytotoxicity. Cancer Res., 54, 6001, 1994.
45. Erikstein B.K., Smeland E.B., Blomhoff H K., et al. Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur. J. Immunol., 21, 1033, 1991.
46. Loetscher H., Gentz R., Zulauf M , Lustig A , Tabuchi H., Schlaeger J., Brockhaus M., et al. Recombinant 55-kDa tumor necrosis factor (TNF) receptor: stochiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. J. Biol. Chem., 266, 18324, 1991.
47. Kyle R A. Why better prognostic factors for multiple myeloma are needed. Blood, 83, 1713, 1994.
48. Alexanian R., Dimopoulos M.A., Delasalle K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887, 1992.